Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 36Carcinoma, Non-Small-Cell Lung 36Multiple Myeloma 26Breast Neoplasms 26Glioma 23Carcinoma, Renal Cell 22Pancreatic Neoplasms 21Melanoma 21Glioblastoma 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Ovarian Neoplasms 19Urinary Bladder Neoplasms 18Lymphoma 18Colorectal Neoplasms 18Triple Negative Breast Neoplasms 15Oropharyngeal Neoplasms 15Mouth Neoplasms 15Brain Neoplasms 15Fallopian Tube Neoplasms 13Carcinoma, Hepatocellular 13Carcinoma 13Laryngeal Neoplasms 12Astrocytoma 12Lymphoma, Follicular 11Leukemia, Myeloid, Acute 11Sarcoma 10Neuroblastoma 10

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡